Scaffdex Oy and Conmed Linvatec Biomaterials Sign a Licensing Agreement of Commercialization and Clinical Data of Joint Prosthesis Innovation
News Sep 15, 2009
Scaffdex Oy and Conmed Linvatec Biomaterials have signed a licensing agreement of commercialization and clinical data of joint prosthesis innovation. Target of Scaffdex Oy is CE marking and launch of this product by end of 2010.
Joint prosthesis replaces small joints in hand and foot and it has been tested clinically for example in rheumatoid arthritis patients. Tampere University Hospital, Hospital of Foundation of Rheumatoid Arthritis in Heinola and clinics in Germany and Italy participated these international clinical trials.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.